Home Why UAMS Giving Referring Patients Employment University and Colleges

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

UAMShealth
Health Library
myUAMShealth
Winthop P. Rockefeller Cancer Institute


 UAMS Facebook UAMS You Tube Channel 
MAKE AN APPOINTMENT MEET OUR STAFF CLINICAL TRIALS CONTACT US

Welcome to the UAMS Myeloma Institute

Recognized Worldwide for Innovation and Cure

Monica Grazziutti, M.D.
Senior Physician, Myeloma Inpatient Unit

The UAMS Myeloma Institute for Research and Therapy is an international leader in the treatment and study of multiple myeloma and related diseases. Our team of dynamic scientists and clinicians translates advances from the laboratory into novel clinical treatments, continually expanding the boundaries of myeloma research and therapy toward cure for all patients.

Why the Myeloma Institute?

  • Thirty-year history of clinical and research knowledge and experience uniquely focused on a single disease—multiple myeloma—and related conditions.
  • Novel "Total Therapy" Approach, designed to attack myeloma up front with a full array of treatment modalities.
  • Proven results: A patient diagnosed with low-risk multiple myeloma who is treated at the Myeloma Institute can expect to survive more than 10 years.
  • Routine use of state-of-the-art genetic profiling to molecularly characterize a patient’s disease and then develop a targeted, individualized treatment plan.
  • Robust clinical trials that incorporate novel treatment approaches to push beyond past successes and further improve patient outcomes.
  • Dedicated supportive care team for management of disease and treatment complexities.
  • Extensive network of support services to facilitate visits for patients traveling to Little Rock.

The Myeloma Institute has pioneered many advances that have become standards of care throughout the world. Read about Unique Features of the Myeloma Institute

News

Claudia Jessup - Multiple Myeloma Survivor

Infection Prevention in Multiple Myeloma Patients

Myeloma Patients Enjoy Games, Each Other

Caring for the Caregiver Program - April 23

Role of Bruton's tyrosine kinase (BTK) in myeloma cell migration and induction of bone disease.

Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with Total Therapy 3

We Have Moved to the Cancer Institute

Abstracts - Annual Meeting of the American Society of Hematology

Grant Award

The IMF at ASH

New High-Tech Tool Aids Hunt for Myeloma Cure

Lenalidomide maintenance for multiple myeloma

Publications: Impediments to Curing Myeloma in 2012

First Clinical Trial for High-Risk Myeloma


VIEW ALL

Patient Connection
Giving
Our Mission
To accelerate curative therapies for multiple myeloma and related disease entities through innovative translational research and outstanding patient care.